Psoriasis studies
A new approach to anti-psoriasis drug development
Preclinical skin models closely mimicking inflammatory features in diseased skin, such as psoriasis, are needed to support the development of anti-inflammatory drugs in dermatology.
Current approaches based on the incorporation of immune cells in reconstructed skin models lack tissue complexity and diversity of immune cells. They also show an incomplete skin barrier function. To overcome these issues, we have developed and characterized a T cell-driven skin inflammation model (InflammaSkin®) based on the NativeSkin® explant technology and assessed pharmacological responses in this model.
Topical psoriasis study
Evaluation of pharmacological responses in InflammaSkin®, a fully human full-thickness ex vivo skin model reproducing key features of psoriatic lesions
Lovato P.1, Jardet C.2, Pagès E.2, David A.2, Braun E.2, Norsgaard H.1, Descargues P.3 ; 1LEO Pharma, Ballerup, Denmark ; 2Genoskin SAS, Toulouse, France ; 3Genoskin Inc. Boston (MA), USA
DOWNLOAD POSTER
